Radiopharm Theranostics Limited (ASX:RAD)
0.0040
0.00 (0.00%)
Oct 21, 2026, 3:58 PM AEST
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2026, Radiopharm Theranostics had annual revenue of 12.87M AUD, down -1.05%. Radiopharm Theranostics had revenue of 6.66M in the half year ending June 30, 2026. That makes Radiopharm Theranostics the 37,795th largest company in the world by revenue and 689th in Australia.
Revenue
12.87M
Revenue Growth
-1.05%
P/S Ratio
1.52
Revenue / Employee
918.94K
Employees
14
Market Cap
19.52M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 12.87M | -136.84K | -1.05% |
| Jun 30, 2025 | 13.00M | 11.41M | 716.81% |
| Jun 30, 2024 | 1.59M | -4.62M | -74.37% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Argenica Therapeutics | 5.48M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Nexsen | 1.09M |
| ReNerve | 510.36K |
| NeuroScientific Biopharmaceuticals | 402.66K |
Radiopharm Theranostics News
- 16 days ago - Radiopharm completes EOP2 meeting with FDA for RAD101 - TheFly
- 21 days ago - Radiopharm Theranostics Annual report: H2 2026 - Filings
- 5 weeks ago - Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up - Nasdaq
- 5 weeks ago - Radiopharm Theranostics Registration statement: Registration filing - Filings
- 6 weeks ago - Radiopharm announces data from imaging trial of RAD 301 - TheFly
- 6 weeks ago - Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 1 month ago - Radiopharm doses first patient in second cohort of RV-01 trial - TheFly
- 1 month ago - Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors - GlobeNewsWire